Drug Profile
Grass pollen allergy vaccine tablet - ALK-Abello
Alternative Names: ALK Tablet; Grass AIT; Grass pollen allergy therapy - ALK-Abello; Grastek; Grazax; Grazax-R; MK-7243; P.-pratense-allergy-immunotherapy-ALK-Abello; P.-pratense-extract-ALK-Abello; P.-pratense-pollen-extract-ALK-Abello; Phelum-pratense-extract-ALK-Abello; Phleum pratense pollen extract; Phleum-pratense-allegy-immunotherapy-ALK-Abello; Phleum-pratense-pollen-extract-ALK-Abello; SCH-697243; Standardized-allergenic-extract-Timothy-grass; Timothy-grass-pollen-allergen-extract-(Grazax); Timothy-grass-pollen-allergy-immunotherapy-ALK-Abello; Timothy-grass-pollen-allergy-therapy-ALK-Abello; Timothy-grass-pollen-allergy-vaccine-ALK-Abello; Timothy-grass-sublingual-tablet-standardized-allergenic-extractLatest Information Update: 14 Dec 2023
Price :
$50
*
At a glance
- Originator ALK-Abello
- Developer Abbott Laboratories; ALK-Abello; Merck & Co; Seqirus
- Class Allergens; Antiallergics; Plant allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Seasonal allergic rhinitis
- Phase III Allergic asthma
Most Recent Events
- 13 Dec 2023 ALK and Torii Pharmaceuticals agree to co-develop Grass pollen allergy vaccine tablet for Seasonal allergic rhinitis
- 16 Apr 2021 Discontinued - Preregistration for Seasonal allergic rhinitis in Russia (Sublingual)
- 07 Jul 2017 Launched for Seasonal allergic rhinitis in Australia (Sublingual)